Eli Lilly agreed to acquire Kelonia Therapeutics in a deal worth up to $7 billion, expanding the company’s in vivo CAR-T ambitions for multiple myeloma and beyond. Lilly will pay $3.25 billion upfront, with additional milestone payments tied to clinical, regulatory and commercial outcomes, with the transaction expected to close in the second half of 2026.